CompletedPhase 2

Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

United States30 participantsStarted 2000-05

Plain-language summary

RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer. PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have refractory or advanced lung cancer.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of a primary or secondary intrathoracic malignancy * Any cell type or origin * Involving the intrapulmonary, mediastinal, or pleural/chest wall * Inoperable primary or metastatic cancer to the lung * Refractory to or not amenable to conventional therapy (e.g., surgery, chemotherapy, or radiotherapy) * Single or multiple lesions that are non-contiguous with vital structures or organs such as: * Trachea * Heart * Aorta * Great vessels * Esophagus * Less than 5 cm in largest dimension * Accessible via percutaneous transthoracic route * Hepatic: * Coagulation profile normal

Trial details

NCT IDNCT00024076

SponsorJonsson Comprehensive Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2006-12

View on ClinicalTrials.gov More Lung Cancer trials